Abstract: A UE may obtain one or more measurements of at least one cell of a network based on a first connection with the network. The UE may reuse at least a first measurement of the one or more measurements for a second connection with the network. The first connection with the network and the second connection with the network may be associated with different subscriptions or different RATs. To reuse at least the first measurement of the one or more measurements for the second connection with the network, the UE may skip a cell detection operation associated with the second connection with the network.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network entity, an absolute threshold synchronization signal block (SSB) consolidation parameter. The TUE may determine whether a threshold value indicated in the absolute threshold SSB consolidation parameter satisfies a predefined value threshold. The UE may set a specific network deployment flag based at least in part on whether the threshold value satisfies the predefined value threshold. The UE may determine a cell measurement result based at least in part on the specific network deployment flag. The UE may perform a downlink beam selection and a beam switch evaluation based at least in part on the specific network deployment flag. Numerous other aspects are described.

Abstract: The UE may store target cell information to a database based on performing a handover to the target cell and detecting the ping-pong handover based on a number of handover instances in the database of the target cell to which the UE has performed the handover being greater than or equal to a threshold number of the handover instances within a period of time. The UE may receive, from a base station a list of ping-pong cell candidates and configure the number of handover instances of the target cell and/or the period of time based on the list of ping-pong cell candidates. The UE may avoid or reduce the handover to the identified ping-pong cell based on the detected ping-pong handover by applying an offset to the measurement of the target cell.

Abstract: In various examples, latency of human interface devices (HIDs) may be accounted for in determining an end-to-end latency of a system. For example, when an input is received at an HID, an amount of time for the input to reach a connected device may be computed by the HID and included in a data packet transmitted by the HID device to the connected device. The addition of the peripheral latency to the end-to-end latency determination may provide a more comprehensive latency result for the system and, where the peripheral latency of an HID is determined to have a non-negligible contribution to the end-to-end latency, a new HID component may be implemented, a configuration setting associated with the HID component may be updated, and/or other actions may be taken to reduce the contribution of the peripheral latency to the overall latency of the system.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from an application processor associated with the UE, an indication of a traffic service type and whether an uplink data stall has occurred. The UE may detect that one or more threshold criteria are satisfied for a serving cell, wherein a threshold value associated with at least one of the one or more threshold criteria is based at least in part on the traffic service type. The UE may transmit information associated with one or more adjusted measurement values of the serving cell based at least in part on detecting that the one or more threshold criteria are satisfied. Numerous other aspects are described.

Abstract: A datacenter power management system and method is disclosed. A plurality of computing units are enabled to operate at a second frequency, higher than a first frequency, in response to determining from respective power coefficients for these computing units, that a power level at this higher frequency remains below a power budget.

Abstract: In a wavelength selective switch, an input port transmits an input beam, and diffraction grating disperses the input beam into optical channels. A liquid-crystal-on-silicon (LCoS) switch assembly has a phase grating profile and has addressable pixels, which are liquid crystal based. The LCoS switch assembly can selectively direct first-order diffracted beams of the optical channels for output to selected output ports. A tunable optical wedge adjacent the LCoS switch assembly can direct higher-order diffraction beams in the space between the output ports to reduce crosstalk. The wedge is a liquid crystal cell having spaced-apart resistive layers and having liquid crystal material disposed between the layers. In the wedge, the liquid crystal material can produce a phase profile in response to bias voltages applied to the resistive layers, and a beam steering angle of the phase profile can direct at least the second-order diffracted beams towards the port spacing between the ports.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.

Abstract: A datacenter power management system and method is disclosed.

Abstract: A two-step optimization process is utilized to define an optimal phase profile for a LCoS spatial light modulator. The two-step optimization process first utilizes a nonlinear constrained optimization (NCO) program to determine the specific parameters required to obtain an optimal phase profile (hologram), where the “optimal phase profile” is typically defined as that profile which achieves maximum diffraction efficiency for optical switching. Following this first step, phase scaling (and perhaps an adjustment in the number of pixels per period) is employed to slightly modify the values of the optimal phase profile to effectively suppress crosstalk peaks. If any orders still exhibit an unacceptable level of crosstalk, these orders are then subtracted from the phase profile to create the final design.

Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.

Abstract: A two-step optimization process is utilized to define an optimal phase profile for a LCoS spatial light modulator. The two-step optimization process first utilizes a nonlinear constrained optimization (NCO) program to determine the specific parameters required to obtain an optimal phase profile (hologram), where the “optimal phase profile” is typically defined as that profile which achieves maximum diffraction efficiency for optical switching. Following this first step, phase scaling (and perhaps an adjustment in the number of pixels per period) is employed to slightly modify the values of the optimal phase profile to effectively suppress crosstalk peaks. If any orders still exhibit an unacceptable level of crosstalk, these orders are then subtracted from the phase profile to create the final design.

Abstract: A multiple wavelength selective switch has an optics assembly to receive a first input optical signal from a first ingress port and a second input optical signal from a second ingress port. A switch assembly has a single switching mechanism to direct the first input optical signal to the optics assembly as a first output optical signal and the second input optical signal to the optics assembly as a second output optical signal. The switch assembly directs the first output optical signal to a first egress port selected from the first set of egress ports and directs the second output optical signal to a second egress port selected from the second set egress ports. The first egress port and the second egress port have the same wavelength channel. The multiple wavelength selective switch supports an arbitrary number of wavelength channels that can be switched at the same time. Each switch assembly directs signals from a set of ingress ports to a set of egress ports sharing the same wavelength channel.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.

Abstract: A dual-band input transceiver block is formed to operably receive one of a 2.4 GHz radio frequency signal or a 5.0 GHz radio frequency transceiver signal in a manner that minimizes duplication of circuitry and creates a combined circuit path for RF front end input stages for much of the input stage. More specifically, the embodiments of the present invention include separate amplification and mixing stages whose outputs are combined by a stabilized load with circuitry for removing a common mode feedback signal. As such, downstream components, such as amplifiers, filters, analog-to-digital converters, and other input path circuit elements, are not duplicated and may be used regardless of whether the dual-band transceiver is operating in a first or second frequency band. Operation is, in the described embodiment, only one frequency input at a time though the invention is not limited to such operation.